Kymera Therapeutics (NASDAQ:KYMR) Issues Earnings Results

Kymera Therapeutics (NASDAQ:KYMR) posted its quarterly earnings results on Wednesday. The company reported ($0.62) EPS for the quarter, beating the consensus estimate of ($0.71) by $0.09, FiscalAI reports. Kymera Therapeutics had a negative net margin of 611.94% and a negative return on equity of 24.71%. The business had revenue of $65.00 million during the quarter, compared to analyst estimates of $32.78 million. During the same quarter in the previous year, the business posted ($0.95) EPS. The company’s quarterly revenue was up 465.2% compared to the same quarter last year.

Here are the key takeaways from Kymera Therapeutics’ conference call:

• KT-621’s atopic dermatitis Phase IIb trial completed enrollment six months early, with top-line data now expected by year-end 2026 and Phase III initiation targeted for mid-2027. Management believes the oral, once-daily profile could substantially expand systemic treatment in type 2 inflammatory diseases.
• The asthma Phase IIb trial is enrolling and remains on track for top-line results by late 2027, while an open-label extension will provide up to 52 additional weeks of safety and efficacy data. The company also expects KT-579 healthy-volunteer data in Q4 2026 before advancing into lupus proof-of-concept studies.
• Partnered programs continue to advance, including Sanofi’s KT-485 Phase I start, which generated a $20 million milestone, and Gilead’s $45 million option exercise fee. Gilead’s KT-200 is expected to enter clinical development next year.
• Kymera ended June with approximately $1.5 billion in cash and investments and reiterated a cash runway into 2029. Management expects this funding to support current Phase II programs, KT-579 through lupus proof of concept, and the beginnings of KT-621 Phase III development.
• The company recognized all currently deferred collaboration revenue in the second quarter, totaling $65 million, and does not expect additional revenue in 2026 absent new milestones. R&D cash spending rose 22% sequentially to $109.1 million as clinical investment increases.

Kymera Therapeutics Stock Performance

KYMR traded up $1.19 during trading on Wednesday, hitting $105.58. The stock had a trading volume of 362,753 shares, compared to its average volume of 739,167. The stock has a 50 day simple moving average of $99.82 and a two-hundred day simple moving average of $88.16. Kymera Therapeutics has a twelve month low of $36.65 and a twelve month high of $130.05. The company has a market capitalization of $8.68 billion, a PE ratio of -29.57 and a beta of 1.95.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on KYMR. Deutsche Bank Aktiengesellschaft started coverage on shares of Kymera Therapeutics in a report on Thursday, July 30th. They set a “hold” rating and a $120.00 price objective on the stock. Morgan Stanley reaffirmed an “overweight” rating and set a $119.00 target price on shares of Kymera Therapeutics in a research report on Thursday, April 30th. Loop Capital set a $97.00 price target on Kymera Therapeutics in a report on Monday, June 8th. B. Riley Financial upped their price objective on Kymera Therapeutics from $117.00 to $155.00 and gave the stock a “buy” rating in a research note on Monday, June 29th. Finally, Royal Bank Of Canada downgraded Kymera Therapeutics from an “outperform” rating to a “sector perform” rating and raised their price objective for the company from $106.00 to $115.00 in a research report on Monday, July 13th. Twenty investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Kymera Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $124.48.

Insiders Place Their Bets

In related news, CEO Nello Mainolfi sold 80,000 shares of the company’s stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $115.29, for a total transaction of $9,223,200.00. Following the transaction, the chief executive officer directly owned 666,568 shares of the company’s stock, valued at $76,848,624.72. This represents a 10.72% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CFO Bruce N. Jacobs sold 77,109 shares of the business’s stock in a transaction dated Tuesday, June 30th. The stock was sold at an average price of $114.96, for a total value of $8,864,450.64. Following the sale, the chief financial officer owned 244,883 shares in the company, valued at $28,151,749.68. The trade was a 23.95% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 3,607,813 shares of company stock valued at $387,818,004. Company insiders own 15.98% of the company’s stock.

Institutional Trading of Kymera Therapeutics

Institutional investors have recently bought and sold shares of the stock. Smartleaf Asset Management LLC increased its stake in Kymera Therapeutics by 382.0% during the 4th quarter. Smartleaf Asset Management LLC now owns 535 shares of the company’s stock valued at $42,000 after purchasing an additional 424 shares in the last quarter. Larson Financial Group LLC grew its holdings in shares of Kymera Therapeutics by 81.5% during the third quarter. Larson Financial Group LLC now owns 777 shares of the company’s stock valued at $44,000 after buying an additional 349 shares during the last quarter. Osaic Holdings Inc. grew its holdings in shares of Kymera Therapeutics by 18,050.0% during the second quarter. Osaic Holdings Inc. now owns 1,089 shares of the company’s stock valued at $48,000 after buying an additional 1,083 shares during the last quarter. Caitong International Asset Management Co. Ltd acquired a new position in shares of Kymera Therapeutics in the 4th quarter valued at $63,000. Finally, Raymond James Financial Inc. purchased a new position in Kymera Therapeutics in the 2nd quarter worth $73,000.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.